Isoptine

Verapamil, the active ingredient in Isoptine, is a calcium channel blocker presented as an oral tablet for oral use. It is employed to manage high blood pressure, relieve chest pain from angina, and control certain rapid heart rhythms in adult patients.

GNH USA supplies Isoptine as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and ensures product integrity throughout the supply chain, delivering reliable global distribution.

Isoptine (verapamil) acts on the cardiovascular system to lower blood pressure and modulate heart rhythm.

- Hypertension: reduces systemic blood pressure by relaxing vascular smooth muscle. - Angina pectoris: alleviates chest pain by decreasing myocardial oxygen demand. - Supraventricular tachyarrhythmias: controls rapid heart rates by slowing atrioventricular conduction.

Verapamil may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Constipation: reduced gastrointestinal motility. - Dizziness or light‑headedness: transient hypotension. - Headache: vascular dilation in the cranial circulation. - Flushing: peripheral vasodilation. - Peripheral edema: fluid accumulation in lower limbs. - Nausea: mild gastrointestinal upset.

Serious or Rare Side Effects: - Bradycardia: markedly slowed heart rate. - Severe hypotension: dangerous drop in blood pressure. - AV block or heart block: impaired electrical conduction. - Hepatic enzyme elevation: potential liver injury. - Allergic reactions: rash, pruritus, or anaphylaxis. - Cardiac failure exacerbation: worsening of pre‑existing heart failure.

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Cardiac function assessment: review baseline ECG and heart rate. - Concomitant drug review: identify agents that may amplify cardiac effects. - Hepatic impairment caution: dose adjustments may be required. - Discontinuation guidance: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Verapamil interacts with several medicines; awareness of interaction severity guides clinical decisions.

Major Interactions (Avoid): - Beta‑blockers: additive bradycardia and AV block. - Digoxin: increased serum digoxin levels, risking toxicity. - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): elevated verapamil concentrations. - Diltiazem: combined calcium‑channel blockade may cause severe hypotension. - Quinidine: heightened risk of cardiac conduction disturbances.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduced verapamil efficacy. - NSAIDs: may blunt antihypertensive effect. - Diuretics: potential electrolyte imbalances, especially potassium. - Statins metabolized by CYP3A4 (e.g., simvastatin): increased risk of myopathy. - Alcohol: can enhance hypotensive response.